See All Slides - tctmd.com

Slides

Presentation TCT 2012

Do Statins and Other Therapies Alter Vulnerable Plaque Characteristics? Insights from Imaging

Presenter: Pedro Moreno

October 23, 2012

Presentation TCT 2012

Nanoparticle-based Therapies for Atherosclerosis: The NANOM FIM Study

Presenter: Alexander Kharlamov

October 23, 2012

Presentation TCT 2012

Radial Approach for NSTEMI: Case Closed or Worth Changing Practice?

Presenter: Robert Applegate

October 23, 2012

Presentation TCT 2012

Overview 2: Biological Therapies for Heart Failure: Regulatory Perspectives

Presenter: Steve Winitsky

October 23, 2012

Presentation TCT 2012

TCT-61. Infarct Size-Determined Uptake of CD34+ Cells in the Peri-Infarct Zone and Left Ventricular Remodeling: Insights from Integration of Labeled Cells Uptake SPECT...

Presenter: Piotr Musialek

October 23, 2012

Presentation TCT 2012

Background Medical and Device Therapies for Patients with VADs

Presenter: Emma Birks

October 23, 2012

Presentation TCT 2012

ELM Presentation(8)

Presenter: Paul Sorajja

October 23, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: BRIDGE-ACS (Multimodality Approach to Adherence), INFUSE-AMI (STEMI), and IMMEDIATE (GIK)

Presenter: Ajay Kirtane

October 23, 2012

Presentation TCT 2012

Therapies Based on ApoA1 and ApoA1 Milano: Overview of the Field

Presenter: Bryan Brewster

October 23, 2012

Presentation TCT 2012

Appropriateness Criteria: Implications for Clinical Practice

Presenter: Monica Losquadro

October 23, 2012

Advertisement

Slides

Do Statins and Other Therapies Alter Vulnerable Plaque Characteristics? Insights from Imaging

Nanoparticle-based Therapies for Atherosclerosis: The NANOM FIM Study

Radial Approach for NSTEMI: Case Closed or Worth Changing Practice?

Overview 2: Biological Therapies for Heart Failure: Regulatory Perspectives

TCT-61. Infarct Size-Determined Uptake of CD34+ Cells in the Peri-Infarct Zone and Left Ventricular Remodeling: Insights from Integration of Labeled Cells Uptake SPECT...

Background Medical and Device Therapies for Patients with VADs

ELM Presentation(8)

Late Breaking Clinical Trials: BRIDGE-ACS (Multimodality Approach to Adherence), INFUSE-AMI (STEMI), and IMMEDIATE (GIK)

Therapies Based on ApoA1 and ApoA1 Milano: Overview of the Field

Appropriateness Criteria: Implications for Clinical Practice

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content